TIGIT and cancer: JAVELIN Bladder Medley (NCT05327530) is a phase II, multicenter, randomized, open-label, parallel-arm study that will assess whether the combination of other anti-cancer drugs (Sacituzumab Govitecan, the anti-TIGIT antibody M6223, or the polymer-conjugated human IL-15 called NKTR-255) with avelumab maintenance can contribute to a further improvement in survival for patients with aUC.